

REMARKS

The Office Action has been carefully reviewed. No claim is allowed. Claims 17-22, 24-27, 29-33 and 35-37 presently appear in this application and define patentable subject matter warranting their allowance. Reconsideration and allowance are hereby respectfully solicited.

Claims 17-22, 24-33, and 35-37 have been rejected under 35 U.S.C. §112, first paragraph, for the reasons of record set forth in Paper no. 10. The examiner states that the instant specification is however enabling for a method of treating or preventing the rejection of organ transplantation by administering a pharmaceutical composition comprising an antagonist for the RANTES receptor, in combination with cyclosporin and a pharmaceutical composition comprising antagonist for the chemokine receptor RANTES and cyclosporin.

This rejection is now obviated by the amendments to the claims. While the claims are amended to now be directed to the subject matter considered by the examiner to be enabled in order to advance applicants' business strategy, applicants however are not conceding the rejection and reserve the right to continue prosecution of broader claims in a continuation application.

Claims 17 and 30 presently recite "a chemokine receptor antagonist for the RANTES receptors" because there is not a single chemokine receptor for RANTES; rather, there at least are


three CC chemokine receptors (CCR1, CCR3, CCR5) that bind RANTES (see specification, page 2, lines 21-26).

Reconsideration and withdrawal of the rejection are therefore respectfully requested.

In view of the above, the claims comply with 35 U.S.C. §112 and define patentable subject matter warranting their allowance. Favorable consideration and early allowance are earnestly urged.

Respectfully submitted,

BROWDY AND NEIMARK, P.L.L.C.
Attorneys for Applicant(s)

By 
Allen C. Yun
Registration No. 37,971

ACY:pp
Telephone No.: (202) 628-5197
Facsimile No.: (202) 737-3528
G:\BN\S\Ser1\Grone1\PTO\amendment for OA 10-22-03.doc